Correlations Between Early MRI Parameters and Long-Term Clinical Outcomes in Phase 3 and Open-Label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study

被引：0

作者：

Arnold, Douglas ^{[1
,2
]}

Freeman, Leorah ^{[3
]}

Hartung, Hans-Peter ^{[4
,5
,6
,7
]}

Montalban, Xavier ^{[8
]}

Cohen, Jeffrey ^{[9
]}

Bar-Or, Amit ^{[10
,11
]}

Steinman, Lawrence ^{[12
]}

DeLuca, John ^{[13
,14
]}

Sheffield, James ^{[15
]}

Cheng, Chun-Yen ^{[15
]}

Riolo, Jon ^{[15
]}

Pachai, Chahin ^{[15
]}

Cree, Bruce A. C. ^{[16
]}

机构：

[1] NeuroRx Res, Montreal, PQ, Canada

[2] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada

[3] Univ Texas Austin, Dell Med Sch, Austin, TX USA

[4] Heinrich Heine Univ, Med Fac, Dusseldorf, Germany

[5] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[6] Med Univ Vienna, Dept Neurol, Vienna, Austria

[7] Palacky Univ Olomouc, Dept Neurol, Olomouc, Czech Republic

[8] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain

[9] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH USA

[10] Univ Penn, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA USA

[11] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA USA

[12] Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr Mol Med, Med Ctr, Stanford, CA USA

[13] Kessler Fdn, West Orange, NJ USA

[14] Rutgers New Jersey Med Sch, Dept Phys Med Rehabil & Neurol Neurosci, Newark, NJ USA

[15] Bristol Myers Squibb, Princeton, NJ USA

[16] Univ Calif San Francisco, Weill Inst Neurosci, Dept Neurol, San Francisco, CA USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1661/518

引用

页码：1050 / 1051

页数：2

共 50 条

[31] Predictors of Relapse in Ozanimod-Treated Patients With Multiple Sclerosis: Ad Hoc Analysis From the Open-Label Extension DAYBREAK Study
Coyle, Patricia
Dunn, Jeffrey Dunn Jeffrey
Kappos, Ludwig
Cheng, Chun-Yen
Thorpe, Andrew
Morello, Jean Pierre
Silva, Diego
Filippi, Massimo
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 957 - 958
[32] Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension
Hauser, Stephen L.
Kappos, Ludwig
Arnold, Douglas L.
Bar-Or, Amit
Brochet, Bruno
Naismith, Robert T.
Traboulsee, Anthony
Wolinsky, Jerry S.
Belachew, Shibeshih
Koendgen, Harold
Levesque, Victoria
Manfrini, Marianna
Model, Fabian
Hubeaux, Stanislas
Mehta, Lahar
Montalban, Xavier
NEUROLOGY, 2020, 95 (13) : E1854 - E1867
[33] Relationship between infections and absolute lymphocyte count during phase 3 and open-label extension trials of ozanimod in patients with relapsing multiple sclerosis
Hartung, H. -P.
Steinman, L.
Bar-Or, A.
Sheffield, J. K.
Harris, S.
Riolo, J. V.
Cheng, C. -Y.
Silva, D.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 622 - 622
[34] Relationship Between Infections and Absolute Lymphocyte Count During Phase 3 and Open-label Extension Trials of Ozanimod in Patients With Relapsing Multiple Sclerosis
Hartung, Hans-Peter
Steinman, Lawrence
Bar-Or, Amit
Sheffield, James K.
Harris, Sarah
Riolo, Jon V.
Cheng, Chun-Yen
Silva, Diego
Cree, Bruce A. C.
NEUROLOGY, 2023, 100 (17)
[35] Long-Term Progression Independent of Relapse Activity Rates and Associated Prediction Model Based on Machine Learning in Phase 3 and Open-Label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis
Kappos, Ludwig
Arnold, Douglas
Pachai, Chahin
Eddy, Nathanial
Osik, Jason
Cheng, Chun-Yen
Harris, Sarah
Riolo, Jon
Thorpe, Andrew
DeBoer, Erik
Freeman, Leorah
Granziera, Cristina
Filippi, Massimo
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1150 - 1152
[36] Absolute Lymphocyte Count Around Infections During Phase 3 and Open-Label Extension Trials of Ozanimod in Participants With Relapsing Multiple Sclerosis
Hartung, Hans-Peter
Steinman, Lawrence
Bar-Or, Amit
Sheffield, James
Harris, Sarah
Riolo, Jon
Cheng, Chun-Yen
Reardon, Jennifer
Thorpe, Andrew
Cree, Bruce
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 354 - 354
[37] United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates
Wolinksy, JS
Narayana, PA
Johnson, KP
MULTIPLE SCLEROSIS, 2001, 7 (01): : 33 - 41
[38] LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
Riedl, M.
Cicardi, M.
Hao, J.
Lu, P.
Li, H.
Manning, M.
Bernstein, J.
Busse, P.
Tachdjian, R.
Gower, R.
Wedner, H.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S31
[39] Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy
Barratt, Jonathan
Barbour, Sean
Brenner, Robert
Cooper, Kerry
Wei, Xuelian
Eren, Necmi
Floege, Juergen
Jha, Vivekanand
Kim, Sung Gyun
Maes, Bart
Phoon, Richard K. S.
Singh, Harmeet
Tesar, Vladimir
Lafayette, Richard
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024,
[40] Long-term treatment with zonisamide: Results of a 2 year open-label extension study
Wroe, S.
Duncan, R.
EPILEPSIA, 2006, 47 : 138 - 138

← 1 2 3 4 5 →